Vulvar Pain pp 129-148 | Cite as

Vulvar Pain After the Menopause

  • Alessandra Graziottin
  • Filippo Murina


Women have a much longer life expectancy than men: around 80–85 years of age in the high-income countries. This means 30–35 years after the menopause. This translates into an incredible gain in life duration (30 years on average) in comparison to only 100 years ago, when the mean life expectancy for women, in Western Europe for example, was 48 years.


Vulvar Cancer Lichen Sclerosus Health Expectancy Genital Arousal Vaginal Atrophy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abraham L, Pinkerton JV, Messig M, Ryan KA, Komm BS, Mirkin S. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene. Maturitas. 2014;78(3):212–8. doi: 10.1016/j.maturitas.2014.04.008. Epub 2014 Apr 26.CrossRefPubMedGoogle Scholar
  2. Alkatout I, Schubert M, Garbrecht N, Weigel MT, Jonat W, Mundhenke C, Gunther V. Vulvar cancer: epidemiology, clinical presentation, and management options. Int J Womens Health. 2015;7:305–13. doi: 10.2147/IJWH.S68979. eCollection 2015.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric. 2010;13(2):132–40.CrossRefPubMedGoogle Scholar
  4. Bouchard C, Labrie F, Derogatis L, Girard G, Ayotte N, Gallagher J, Cusan L, Archer DF, Portman D, Lavoie L, Beauregard A, Côté I, Martel C, Vaillancourt M, Balser J, Moyneur E, other participating Members of the VVA Prasterone Group. Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study. Horm Mol Biol Clin Investig. 2016;25(3):181–90.PubMedGoogle Scholar
  5. Bruyniks N, Nappi RE, Castelo-Branco C, de Villiers TJ, Simon J. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy. Climacteric. 2016;19(1):60–5.CrossRefPubMedGoogle Scholar
  6. Chi CC, Kirtschig G, Baldo M, Brackenbury F, Lewis F, Wojnarowska F. Topical interventions for genital lichen sclerosus. Cochrane Database Syst Rev. 2011;(12):CD008240.Google Scholar
  7. Corsini E, Galbiati V, Papale A, Kummer E, Pinto A, Serafini MM, Guaita A, Spezzano R, Caruso D, Marinovich M, Racchi M. Role of androgens in dhea-induced rack1 expression and cytokine modulation in monocytes. Immun Ageing. 2016;13:20. doi: 10.1186/s12979-016-0075-y. eCollection 2016.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Cui Y, Zong H, Yan H, Li N, Zhang Y. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J Sex Med. 2014;11(2):487–97.CrossRefPubMedGoogle Scholar
  9. Davis SR, Worsley R, Miller KK, Parish SJ, Santoro N. Androgens and female sexual function and dysfunction – findings from the fourth international consultation of sexual medicine. J Sex Med. 2016;13(2):168–78.CrossRefPubMedGoogle Scholar
  10. Del Pup L, Postruznik D, Corona G. Effect of one-month treatment with vaginal promestriene on serum estrone sulfate levels in cancer patients: a pilot study. Maturitas. 2012;72:93–4.CrossRefPubMedGoogle Scholar
  11. DeRogatis LR, Graziottin A, Bitzer J, Schmitt S, Koochaki PE, Rodenberg C. Clinically relevant changes in sexual desire, satisfying sexual activity and personal distress as measured by the profile of female sexual function, sexual activity log, and personal distress scale in postmenopausal women with hypoactive sexual desire disorder. J Sex Med. 2009;6(1):175–8.CrossRefPubMedGoogle Scholar
  12. Diagnostic and statistical manual of mental disorders fifth edition (DSM V). American Psychiatric Association Ed. 2015.Google Scholar
  13. Freedman MA. Vaginal pH, estrogen and genital atrophy. Menopause Manag. 2009;17(4):9–13.Google Scholar
  14. Gambacciani M, Torelli MG, Martella L, Bracco GL, Casagrande AG, Albertin E, Tabanelli S, Viglietta M, D’Ambrogio G, Garone G, Cervigni M. Rationale and design for the Vaginal Erbium Laser Academy Study (VELAS): an international multicenter observational study on genitourinary syndrome of menopause and stress urinary incontinence. Climacteric. 2015;18 Suppl 1:43–8.CrossRefPubMedGoogle Scholar
  15. Gass MLS, Cochrane BB, Larson JC, et al. Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women’s Health Initiative. Menopause. 2011;18(11):1160–71.CrossRefPubMedGoogle Scholar
  16. Goetsch M. Postpartum dyspareunia – an unexplored problem. J Reprod Med. 1999;44:963–8.PubMedGoogle Scholar
  17. Goldstein AT, King MA. Ospemifene may not treat vulvar atrophy: a report of two cases. Sex Med. 2016;4(3):e217–20.CrossRefPubMedPubMedCentralGoogle Scholar
  18. Graziottin A. Recurrent cystitis after intercourse: why the gynaecologist has a say. In: Studd J, Seang LT, Chervenak FA, editors. Current progress in obstetrics and gynaecology, vol. 2. Mumbai: Suketu P. Kothari – TreeLife Media; 2014. p. 319–36.Google Scholar
  19. Graziottin A. Unmet needs in vulvovaginal atrophy (VVA). Abstract book, 10th Congress of the European Menopause Society on “Promoting translation of science into clinical practice in midlife health and beyond”, Madrid, Spain, May 20–22, 2015b, Maturitas 82(3):320–1, Nov 2015.Google Scholar
  20. Graziottin A. Vaginal biological and sexual health – the unmet needs. Climacteric. 2015a;18 Suppl 1:9–12.Google Scholar
  21. Graziottin A, Gambini D. Anatomy and physiology of genital organs – women. In: Vodusek D, Boller F, editors. Neurology of sexual and bladder disorders (Handbook of clinical neurology, vol. 130, 3rd Series). Edinburgh: Elsevier; 2015. p. 39–60.CrossRefGoogle Scholar
  22. Graziottin A, Gambini D. Female sexual dysfunction: treatment. In: Bø K, Berghmans B, Mørkved S, Van Kampen M, editors. Evidence-based physical therapy for the pelvic floor – bridging science and clinical practice. 2nd ed. Oxford: Elsevier; 2016 (in press).Google Scholar
  23. Graziottin A, Lukasiewicz M. Female sexual dysfunction and premature menopause. In: Lipshultz L, Pastuszek A, Perelman M, Giraldi AM, Buster J, editors. Sexual health in the couple: management of sexual dysfunction in men and women. New York: Springer; 2015 (in press).Google Scholar
  24. Graziottin A, Zanello PP. Pathogenic biofilms: their role in recurrent cystitis and vaginitis (with focus on D-mannose as a new prophylactic strategy). In: Studd J, Seang LT, Chervenak FA, editors. Current progress in obstetrics and gynaecology, vol. 2. 2nd ed. Mumbai: Kothari Medical; 2015 (accepted, in press).Google Scholar
  25. Graziottin A, Gambini D, Bertolasi L. Genital and sexual pain in women. In: Vodusek D, Boller F, editors. Neurology of sexual and bladder disorders (Handbook of clinical neurology, vol. 130, 3rd Series). Edinburgh: Elsevier; 2015. p. 395–412.Google Scholar
  26. Graziottin A, Lukasiewicz M. Psychosexual issues and quality of life after oncologic pelvic surgery, with focus on cervical cancer. In: Carbone A, Palleschi G, Pastore AL, Messas A, editors. Functional urologic surgery in neurogenic and oncologic diseases. Springer; 2016. p. 113–32.Google Scholar
  27. Graziottin A, Lukasiewicz M, Serafini A. Sexual rehabilitation after gynecologic cancers. In: Gianotten W, Reisman Y, editors. Sexual rehabilitation. Springer; 2016 (in press).Google Scholar
  28. Griebling TL, Liao Z, Smith PG. Systemic and topical hormone therapies reduce vaginal innervation density in postmenopausal women. Menopause. 2012;19(6):630–5.CrossRefPubMedPubMedCentralGoogle Scholar
  29. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause. 2010;17(2):281–9.CrossRefPubMedGoogle Scholar
  30. Kao A, Binik YM, Amsel R, Funaro D, Leroux N, Khalife S. Biopsychosocial predictors of postmenopausal dyspareunia: the role of steroid hormones, vulvovaginal atrophy, cognitive-emotional factors, and dyadic adjustment. J Sex Med. 2012a;9:2066–76.CrossRefPubMedGoogle Scholar
  31. Kao A, Binik YM, Amsel R, Funaro D, Leroux N, Khalife S. Challenging atrophied perspectives on postmenopausal dyspareunia: a systematic description and synthesis of pain characteristics. J Sex Marital Ther. 2012b;38:128–50.CrossRefPubMedGoogle Scholar
  32. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10:1790–9.CrossRefPubMedGoogle Scholar
  33. Labrie F, Cusan L, Gomez JL, et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause. 2009;16(1):30–6.CrossRefPubMedGoogle Scholar
  34. Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, VVA Prasterone Research Group. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016;23(3):243–56.CrossRefPubMedGoogle Scholar
  35. Lahaie MA, Amsel R, Khalifé S, Boyer S, Faaborg-Andersen M, Binik YM. Can fear, pain, and muscle tension discriminate vaginismus from dyspareunia/provoked vestibulodynia? Implications for the new DSM-5 diagnosis of genito-pelvic pain/penetration disorder. Arch Sex Behav. 2015;44(6):1537–50.CrossRefPubMedGoogle Scholar
  36. Lukasiewicz ME, Graziottin A. Women’ sexuality after gynecologic cancers. In: Studd J, Seang LT, Chervenak FA, editors. Current progress in obstetrics and gynaecology, vol. 2. 2nd ed. Mumbai: Kothari Medical; 2015 (in press).Google Scholar
  37. MacBride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87–94.CrossRefGoogle Scholar
  38. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888–902.Google Scholar
  39. Martel C, Labrie F, Archer DF, Ke Y, Gonthier R, Simard JN, Lavoie L, Vaillancourt M, Montesino M, Balser J, Moyneur É, Prasterone Clinical Research Group. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. J Steroid Biochem Mol Biol. 2016;159:142–53.CrossRefPubMedGoogle Scholar
  40. Mercier J, Morin M, Lemieux MC, Reichetzer B, Khalifé S, Dumoulin C. Pelvic floor muscles training to reduce symptoms and signs of vulvovaginal atrophy: a case study. Menopause. 2016;23(7):816–20.CrossRefPubMedGoogle Scholar
  41. Nappi RE, Kokot-Kierepa M. Vaginal health: insights, views & attitudes (VIVA) – results from an international survey. Climacteric. 2012;15:36–44.CrossRefPubMedGoogle Scholar
  42. Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. 2014;17:3–9.CrossRefPubMedGoogle Scholar
  43. Nappi RE, Mattsson LÅ, Lachowsky M, Maamari R, Giraldi A. The CLOSER survey: impact of postmenopausal vaginal discomfort on relationships between women and their partners in Northern and Southern Europe. Maturitas. 2013;75:373–9.CrossRefPubMedGoogle Scholar
  44. Nappi RE, Biglia N, Cagnacci A, Di Carlo C, Luisi S, Paoletti AM. Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group. Gynecol Endocrinol. 2016;17:1–5.Google Scholar
  45. Parish SJ, Nappi RE, Krychman ML, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health. 2013;5:437–47.CrossRefPubMedPubMedCentralGoogle Scholar
  46. Phillips NA, Brown C, Foster D, Bachour C, Rawlinson L, Wan J, Bachmann G. Presenting symptoms among premenopausal and postmenopausal women with vulvodynia: a case series. Menopause. 2015;22(12):1296–300.CrossRefPubMedPubMedCentralGoogle Scholar
  47. Pieralli A, Fallani MG, Becorpi A, Bianchi C, Corioni S, Longinotti M, Tredici Z, Guaschino S. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. Arch Gynecol Obstet. 2016;294(4):841–6.CrossRefPubMedGoogle Scholar
  48. Pinkerton JV, Kagan R. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use. Expert Opin Pharmacother. 2015;16(17):2703–14.CrossRefPubMedGoogle Scholar
  49. Pluchino N, Drakopoulos P, Bianchi-Demicheli F, Wenger JM, Petignat P, Genazzani AR. Neurobiology of DHEA and effects on sexuality, mood and cognition. J Steroid Biochem Mol Biol. 2015;145:273–80.CrossRefPubMedGoogle Scholar
  50. Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Maturitas. 2014;79(3):349–54.CrossRefPubMedGoogle Scholar
  51. Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV, Olivera CK, Abed H, Balk EM, Murphy M, Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014;124(6):1147–56.CrossRefPubMedPubMedCentralGoogle Scholar
  52. Reissing ED, Borg C, Spoelstra SK, Ter Kuile MM, Both S, de Jong PJ, van Lankveld JJ, Melles RJ, Weijenborg PT, Weijmar Schultz WC. “Throwing the baby out with the bathwater”: the demise of vaginismus in favor of genito-pelvic pain/penetration disorder. Arch Sex Behav. 2014;43(7):1209–13.CrossRefPubMedGoogle Scholar
  53. REVIVE EU, Abstract presented at EMAS 2015Google Scholar
  54. Salvatore S, Stavros A, Candiani M. The use of pulsed CO2 lasers for the treatment of vulvovaginal atrophy. Curr Opin Obstet Gynecol. 2015;27(6):504–8.Google Scholar
  55. Schneidewind-Skibbe A, Hayes RD, Koochaki PE, Meyer J, Dennerstein L. The frequency of sexual intercourse reported by women: a review of community-based studies and factors limiting their conclusions. J Sex Med. 2008;5(2):301–35.CrossRefPubMedGoogle Scholar
  56. Straub R. The complex role of estrogens in inflammation. Endocr Rev. 2007;28(5):521e74.CrossRefGoogle Scholar
  57. Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13:509–22.CrossRefPubMedGoogle Scholar
  58. Ting AY, Blacklock AD, Smith PG. Estrogen regulates vaginal sensory and autonomic nerve density in the rat. Biol Reprod. 2004;71(4):1397–404.CrossRefPubMedGoogle Scholar
  59. Zoubina E, Smith P. Sympathetic hyperinnervation of the uterus in the estrogen receptor alpha knock-out mouse. Neuroscience. 2001;103:237–44.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Alessandra Graziottin
    • 1
  • Filippo Murina
    • 2
  1. 1.Center of Gynecology and Medical SexologySan Raffaele Resnati HospitalMilanItaly
  2. 2.Lower Genital Tract Disease Unit V. Buzzi HospitalUniversity of MilanMilanItaly

Personalised recommendations